inclusion criteria: * admitted to the hospital with symptoms of covid-19 within 7 days * male and females age ≥18 years old * laboratory confirmed positive sars-cov-2 rtpcr test * clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 * coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln * subject (or legally authorized representative) gives written informed consent prior to performing any study procedures * subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: * admitted to the hospital with symptoms of covid-19 within 7 days * male and females age ≥18 years old * laboratory confirmed positive sars-cov-2 rtpcr test * clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 * coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln * subject (or legally authorized representative) gives written informed consent prior to performing any study procedures * subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: admitted to the hospital with symptoms of covid-19 within 7 days male and females age ≥18 years old laboratory confirmed positive sars-cov-2 rtpcr test clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln subject (or legally authorized representative) gives written informed consent prior to performing any study procedures subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study

inclusion criteria: admitted to the hospital with symptoms of covid-19 within 7 days male and females age ≥18 years old laboratory confirmed positive sars-cov-2 rtpcr test clinical status on the covid-19 ordinal scale (defined in section 5.1) of 3, 4, 5, or 6 coagulation: inr ≤ 1.5×uln, and aptt ≤ 1.5×uln subject (or legally authorized representative) gives written informed consent prior to performing any study procedures subject (or legally authorized representative) agree that subject will not participate in another covid-19 trial while participating in this study